Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE).
Social Media Links
REPORT RATINGS
4.8 / 5.0 (218)
Adverum Biotechnologies, Inc. reports have an aggregate usefulness score of 4.8 based on 218 reviews.